Cite

HARVARD Citation

    Popat, S. et al. (2015). Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future oncology. pp. 409-420. [Online]. 
  
Back to record